SPECIAL REPORT: Understanding Treatment Dynamics and Needs in Juvenile Idiopathic Arthritis

Introduction

Although interviewed thought leaders acknowledge that available biological therapies have greatly improved treatment of juvenile idiopathic arthritis (JIA)-the most common rheumatic disease in children-they do not hesitate to point out unmet needs and remaining drug development opportunities in this field. When current treatments fail, severe disability and even death can result. The heterogeneous nature of JIA leaves room for drugs that target new targets while meeting the particular needs of the pediatric population.

Questions Answered in This Report

• JIA is an umbrella term for seven distinct diagnoses. How are the various JIA subtypes defined? How are they diagnosed? How does their treatment differ?
• The drugs used in the treatment of JIA are identical to those used in adult rheumatic diseases. What are the first-line therapies for JIA? What factors drive prescribing decisions? How safe and efficacious are these treatments in children?
• Not all JIA patients are sufficiently treated with available therapies. Which specific unmet needs remain? What agents are in development for JIA? How will these agents fit into the treatment patterns for these diseases? What do thought leaders say about emerging agents?

Scope

• Overview of JIA: Oligoarthritis; polyarthritis; enthesitis-related arthritis; psoriatic arthritis; systemic JIA; diagnosis of JIA.
• Epidemiology: Ten-year forecast for United States, France, Germany, Italy, Spain, United Kingdom, and Japan.
• Current therapies: nonsteroidal anti-infl ammatory drugs (NSAIDs); corticosteroids; methotrexate; tumor necrosis factor-alpha (TNF-á) inhibitors; Orencia; Kineret; Rituxan.
• Emerging therapies: Rilonacept; canakinumab; tocilizumab.
• Opportunities in JIA: Qualitative market outlook for current and emerging agents; unmet needs.
• Primary research: Thought-leader interviews from the United States, France, Germany, and the United Kingdom.

Please note, the PDF e-mail from publisher version of this report is for a global site license.